The preventive and therapeutic impact of antiplatelet agents: past and present.
Already more than two thousands years ago the Greek physician Hippocrates (V-IV century B.C.) used the extracts of the willow bark to fight fever. At the end of the eighteen hundreds the German chemist Felix Hoffmann obtained acetylsalicylic acid in stable and pure form, and from then on Aspirin (where A is the abbreviation of acetyl and Spir stands for Spirsaure, the German name of salicylic acid) has had enormous diffusion. In 1953 Lawrence Craven reported that he had successfully prescribed aspirin to hundreds of adult male patients for the non-specific prophylaxis of coronary thrombosis. Aspirin is now one of the most well-known drugs in the world, and in the last decades a large body of scientific evidence has appeared with regard to the preventive and therapeutic effects of aspirin and those of other antiplatelet agents. In fact, antiplatelet agents constitute a cornerstone in current pharmacological treatment and prophylaxis. Among the most interesting recent and beneficial areas of impact of aspirin and of other antiplatelet drugs, there are those of stroke and of coronary artery disease, and today targeted pharmacological and non-pharmacological interventions should be carefully combined to deal, preventively and therapeutically, with the cardiovascular epidemic.
Gensini
G F
GF
Conti
A A
AA
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000266:history / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000517:prevention & control*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D049672:History, 19th Century; D049673:History, 20th Century; D049690:History, Ancient; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000266:history / Q000627:therapeutic use*; D020521:Stroke / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin